Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint in Moderate to Severe Knee Osteoarthritis
NCT05603754Phase 3Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing Lorecivivint 0.07 mg with Placebo (2 arms). Primary endpoint: Pain Numeric Rating Scale at 12 weeks. Started Nov 2022; status: completed.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05603754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603754.